Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II profiling trial of alisporivir plus ribavirin in chronic hepatitis C genotype 2 and 3
2012-004185-17Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of alisporivir in hepatitis C virus infection (3 arms), sponsored by Novartis. Primary endpoint: viral load drop from baseline through week 12. Started Jun 2013; status: completed.
02
Drugs
alisporivir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2012-004185-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004185-17.